‘Walking The Walk’ On AMR Report

‘Walking the walk’ on AMR report

The Hindu Business Line talks to Executive Director Jayasree K. Iyer about our forthcoming Antimicrobial Resistance Benchmark and our drive to develop this new tool for tracking company action to tackle AMR.
Continue reading
STAT Examines New PDP Targeting Drug-resistant Bacteria

STAT examines new PDP targeting drug-resistant bacteria

The Foundation's Exectutive Director, Jayasree K. Iyer, talks to STAT about antimicrobial resistance and the importance of a new Public Development Partnership between GARDP and Entasis. The partnership aims to develop a new treatment for multi-drug resistant gonorrhoea.
Continue reading
The Demands Of Disease Drive Science

The demands of disease drive science

Special report on Vaccines by Clive Cookson for FT Health covers the R&D findings of the 2017 Access to Vaccines Index.
Continue reading
More Engagement On Neglected Tropical Diseases Needed From Drugmakers

More engagement on neglected tropical diseases needed from drugmakers

For the special report on NTDs by Gonzalo Viña for the Financial Times, Jayasree K. Iyer talks about examples of positive engagement by pharmaceutical companies in recent years.
Continue reading
Medicijnen Testen On Ask Me Anything, BNR

Medicijnen testen on Ask me Anything, BNR

On the radio show Ask me Anything (BNR Radio, Netherlands) Jörgen Raymann, invited Wim Leereveld, Founder, Access to Medicine Foundation as a guest to discuss and answer audience questions regarding medicine testing.
Continue reading
Novartis Looks To World’s Rich To Meet Need In Chronic Ailments

Novartis Looks to World’s Rich to Meet Need in Chronic Ailments

For his article that focuses on how Novartis seeks to fill funding gap for chronic diseases and is exploring formation of new financing vehicle, James Paton interviews the Foundations Executive Director, Jayasree. K. Iyer.
Continue reading
Vaccination Scorecard

Vaccination Scorecard

Andrew Jack from Financial Times Health, the weekly newsletter on health features the first Access to Vaccines Index in the Chartwatch section of the newsletter.
Continue reading
When It Comes To Needed Vaccines, Pharma Offers A Mixed Bag

When it comes to needed vaccines, pharma offers a mixed bag

Ed Silverman from Stat writes about the first Access to Vaccines Index.
Continue reading
Vaccine Makers Ranked On Pricing And Research

Vaccine Makers Ranked on Pricing and Research

Donald Mc.Neil Jr. from The New York Times writes about the first Access to Vaccines Index and the performance of the companies in Index.
Continue reading
Evaluating Industry’s Role In Vaccine Access

Evaluating industry’s role in vaccine access

The Lancet covers the first Access to Vaccines Index. A summary of the article - On March 6, 2017, the Access to Medicine Foundation released its first Access to Vaccines Index, a baseline analysis of industry activities to improve access to vaccines worldwide.
Continue reading
Vaccins : Un Engagement Variable Des Laboratoires Dans Les Pays Du Sud

Vaccins : un engagement variable des laboratoires dans les pays du Sud

Catherine Ducruet from the French financial daily, Les Echos covers the first Access to Vaccines Index. A summary of the article - GSK et Sanofi sont les plus impliqués, mais une étude note l’intérêt croissant de J&J, Takeda et Daichi Sankyo. Le marché mondial dépasse les 33 milliards de dollars.
Continue reading
GSK And J&J Lead In Vaccines Research – But Pricing Still An Issue

GSK and J&J lead in vaccines research – but pricing still an issue

Andrew McConaghie leads with the finding that GSK and Johnson & Johnson are leading R&D investment in vaccines, and the field is producing the first ever vaccines for conditions such as Ebola
Continue reading
Vaccins Tegen Ebola En Malaria In De Maak

Vaccins tegen ebola en malaria in de maak

In the article, Karel Berkhout covers the publication of the Access to Vaccines Index 2017, in particular referring to the development of new vaccines against ebola and malaria.
Continue reading
Hoop Voor Veel Ernstig Zieken

Hoop voor veel ernstig zieken

Writing in the NRC, Karel Berkhout writes about the need for greater vaccines coverage and the landscape of industry activity uncovered by the Access to Vaccines Index.
Continue reading
‘Fabrikanten Werken Aan Vaccinaties Voor Ebola En Hiv’

‘Fabrikanten werken aan vaccinaties voor ebola en hiv’

The Dutch news website nu.nl covers the first Access to Vaccines Index and mentions that companies are working on vaccines for ebola and HIV.
Continue reading
Save The Children Welcomes The Access To Vaccines Index

Save the Children welcomes the Access to Vaccines Index

Save the Children welcomes the first Access to Vaccines Index as a new catalyst to stimulate action from pharmaceutical companies to improve access to vaccines.
Continue reading
A Helping Hand

A Helping Hand

In the article, Viveka Roychowdhury refers to the performance of the companies in the 2016 Access to Medicine Index as part of the article and interviews Jayasree K. Iyer to shed some more light on the topic.
Continue reading
Access To Medicine Index—what About Sustainability?

Access to Medicine Index—what about sustainability?

David L Heymann comments about the Access to Medicine Index in the Lancet. A summary of the article - A pharmaceutical company representative described the Access to Medicine Index 2016 as “a force for good, and..
Continue reading
Accessing Big Pharma’s Conscience

Accessing Big Pharma’s Conscience

The Medicine Maker interviews Jayasree K. Iyer for their December issue. In the interview, Jayasree discusses the Access to Medicine Foundation, the Access to Medicine Index, performance of the pharmaceutical companies measured as part of the 2016 Access to Medicine Index and the upcoming Access to Vaccines Index.
Continue reading
Speeding Up Access To Medicine For Developing Countries

Speeding up access to medicine for developing countries

Nikkan Kogyo publishes article on the 2016 Access to Medicine Index
Continue reading
Delivery Strategies Rank High For Big Pharma, Now

Delivery strategies rank high for Big Pharma, now

In the article titled 'Delivery strategies rank high for Big Pharma, now', Jyothi Datta writes about the performance of pharma companies in the 2016 Access to Medicine Index.
Continue reading
BBC Talks To Jayasree K. Iyer About Pharma R&D Priorities

BBC talks to Jayasree K. Iyer about pharma R&D priorities

Mike Johnson interviews Jayasree K. Iyer about the importance of pharmaceutical companies remaining active in R&D that addresses the health priorities of people living in low- and middle-income countries without access to medicine.
Continue reading
NOS 1 Covers 2016 Index, Interviews Jayasree K. Iyer

NOS 1 covers 2016 Index, interviews Jayasree K. Iyer

Dutch national news channel NOS 1 covers the publication of the 2016 Access to Medicine Index.
Continue reading
Africa 54 Talks To Jayasree K Iyer About Pharma Activities In Africa

Africa 54 talks to Jayasree K Iyer about pharma activities in Africa

For Africa 54 on Voice of America, Jayasree K. Iyer talks to Linord Moudou.
Continue reading
Drugmakers Improve Access For Poor, GSK Ranked Top

Drugmakers improve access for poor, GSK ranked top

Ben Hirschler and Mark Potter report on the 2016 Access to Medicine Index for Reuters, highlighting how the Index can focus executives' attention on the issue of access to medicine.
Continue reading
Access To Medicine Index Says Industry Is Making ‘moderate Progress’

Access to Medicine Index says industry is making ‘moderate progress’

The Pharmaceutical Journal reports on the industry-level findings from the 2016 Access to Medicine Index, including on progress in pro-access licensing, and the static use of equitable pricing.
Continue reading
Grote Farmaceuten Doen Meer Voor Armen

Grote farmaceuten doen meer voor armen

Ellen de Visser reports on the 2016 Access to Medicine Index (article in Dutch).
Continue reading
Pharmaindustrie Tut Zu Wenig In Der Dritten Welt

Pharmaindustrie tut zu wenig in der Dritten Welt

Patrick Griesser reports on the 2016 Access to Medicine Index, focusing on affordability and R&D pipelines (article in German).
Continue reading
Volop Kansen Voor Farmaceutische Bedrijven In Arme Landen

Volop kansen voor farmaceutische bedrijven in arme landen

Henk Snyders reports on the 2016 Access to Medicine Index, with a focus on affordability of medicines (article in Dutch).
Continue reading
New Pharma Rankings On Global Access To Medicine Released

New Pharma Rankings On Global Access To Medicine Released

Judy Stone reports on the 2016 Access to Medicine Index and refers to some of the main findings, namely those related to R&D, Pricing and Governance & Compliance.
Continue reading
GSK Tops List Of Drug Firms Improving Global Access To Medicine

GSK tops list of drug firms improving global access to medicine

Julia Kollewe reports on how GSK can lead the Access to Medicine Index for the fifth time in 2016, while its British peer AstraZeneca climbs into the top 10.
Continue reading
Which Big Drug Companies Are Helping The Poor? Here’s The List

Which Big Drug Companies Are Helping the Poor? Here’s the List

Donald G McNeil Jr covers the 2016 Access to Medicine Index, with a focus on the power of company CEO's to set the pace of change.
Continue reading
Which Drug Makers Do A Good Job Getting Poor Patients Access To Their Medicines?

Which drug makers do a good job getting poor patients access to their medicines?

In the Pharmalot column, Ed Silverman reports on the companies at the top of the 2016 Access to Medicine Index, quoting Foundation Executive Director, Jayasree K. Iyer, on where there are still opportunities to do more.
Continue reading
Drug Firms Need To Tackle Affordability

Drug firms need to tackle affordability

Anne Gulland reports on the 2016 Access to Medicine Index for the BMJ, covering the ranking itself and the main findings from the Index report.
Continue reading
Dure Pillen Doen Ons Nu Allemaal Pijn

Dure pillen doen ons nu allemaal pijn

Karel Berkhout interviews Jayasree K. Iyer, Executive Director, Access to Medicine Foundation on the impact of availability and affordability of medicines (interview in Dutch).
Continue reading
Meer Beleggers Willen Goedkope Medicijnen Voor De Armen

Meer beleggers willen goedkope medicijnen voor de armen

Karel Berkhout reports on the 2016 Access to Medicine Index, describing the importance of the ranking for responsible investors (article in Dutch).
Continue reading
Big Pharma Is Failing To Do Enough For Poor Countries

Big pharma is failing to do enough for poor countries

Gonzalo Viña covers the 2016 Access to Medicine Index for the Financial Times. He focuses on the companies ranked in the lower half of the Index, and cites the finding that the industry as a pack is making little progress in key areas, particularly in affordability.
Continue reading
Access To Medicine Index Finds Progress In Pharma’s Efforts

Access To Medicine Index Finds Progress In Pharma’s Efforts

Writing for Intellectual Property Watch, Catherine Saez reports on the main findings of the 2016 Access to Medicine Index, focusing on its overal analysis of how the industry approaches the international agreement on the Trade Related Aspects of Intellectual Property Rights (TRIPS) and compulsory licences.
Continue reading
Suzanne Wolf Discusses New 2016 Access To Medicine Index On NOS Radio 1 Journaal

Suzanne Wolf discusses new 2016 Access to Medicine Index on NOS Radio 1 Journaal

Writing for Intellectual Property Watch, Catherine Saez reports on the main findings of the 2016 Access to Medicine Index, focusing on its overal analysis of how the industry approaches the international agreement on the Trade Related Aspects of Intellectual Property Rights (TRIPS) and compulsory licences.
Continue reading
Jayasree K. Iyer Among Experts Consulted For Fortune’s ‘Change The World’ List

Jayasree K. Iyer among experts consulted for Fortune’s ‘Change the World’ list

Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation was amongst the experts consulted by the team at Fortune magazine for their 2016 companies 'Change the World' list. Other experts consulted were Michael Porter from Harvard Business School, Joey Reiman from Emroy University, Rick Wartzman from the Drucker Institute, Joe Arval from the University of Michigan, Dominic Barton from McKinsey, Robert Blood from Sigwatch, Mark Kramer from FSG, Bob Metcalfe from MIT Innovative Initiative, Wayne Pacelle from Humane Society of the United States, UN Foundation and the Clinton Global Initiative.
Continue reading
Access To Medicine Index Mentioned In An Article In Neue Zürcher Zeitung

Access to Medicine Index mentioned in an article in Neue Zürcher Zeitung

In the article titled 'Teure Medikamente erhöhen den Druck', guest columnist Simon Schmid writes about pricing, patents and licencing and their inteconnectedness in the pharmaceutical industry. The article mentions increased transparency in patent portfolios of AstraZeneca, Merck and Novo Nordisk as an example and how this move not only is of interest to public health but also brings helps the company ranking in the Access to Medicine Index.
Continue reading
ET Healthworld Interviews Jayasree K. Iyer On Access To Vaccines Index

ET Healthworld interviews Jayasree K. Iyer on Access to Vaccines Index

Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation, talks about the importance of vaccines and the role of vaccine manufacturers in ensuring they reach the people who need them. She touches on vaccine access in India and discusses the Access to Vaccines Index, a new tool for tracking how vaccine companies are improving access to their products.
Continue reading
Jayasree K. Iyer Featured In The Medicine Maker Power List 2016

Jayasree K. Iyer featured in The Medicine Maker Power List 2016

Jayasree K. Iyer featured among the top 100 influential people

Continue reading
Article On Innovations In Access To Medicines Underway Quotes Jayasree K. Iyer

Article on innovations in access to medicines underway quotes Jayasree K. Iyer

As part of the 'Access to Medicine' campaign, Andrew Green quotes Jayasree K. Iyer, Executive Director, on innovations needed to spur improved access to medicines for people in the developing world. The article 'From communities to global policy: Innovations to access medicines underway' covers the innovations being introduced by range of actors at all points in the process — from creation to distribution — in an attempt to create access to medicine for people in developing countries.
Continue reading
Jayasree K. Iyer Comments In The Special Report On Vaccines On FT

Jayasree K. Iyer comments in the Special Report on Vaccines on FT

In the special report on vaccines titled, Vaccines are among big pharma's best selling products published in the Financial Times, Jayasree K. Iyer comments on Sanofi’s new vaccine for dengue fever and the need for Sanofi to plan to create wide access for it.
Continue reading
Damiano De Felice Interviewed On Big Pharma And Access To Medicine

Damiano de Felice interviewed on big pharma and access to medicine

Damiano de Felice, Deputy Director of Strategy at the Access to Medicine Foundation speaks to ETicaNews on how inclusive and sustainable business models of pharmaceutical companies help facilitate access to medicine. ETicaNews is a website for professionals interested and involved in responsible investing and responsible business conduct.
Continue reading
Jayasree K. Iyer Comments On What GSK’s New Patent Policy Means For The Developing World

Jayasree K. Iyer comments on what GSK’s new patent policy means for the developing world

In the article, Jayasree K. Iyer comments on the effect of GSK's move on other companies with bigger cancer portfolios.
Continue reading
Danny Edwards Analyses The Impact Of GSK’s Approach To IP And Patents On Access To Medicine

Danny Edwards analyses the impact of GSK’s approach to IP and Patents on Access to Medicine

Danny Edwards analyses the impact of GSK's approach to Intellectual Property and Patents on Access to Medicine on Radio France International.
Continue reading
Jayasree K. Iyer Comments On GSK’s Approach To IP And Patents On Access To Medicine

Jayasree K. Iyer comments on GSK’s approach to IP and Patents on Access to Medicine

Jayasree K. Iyer shares her views on the announcement made by Sir Andrew Witty regarding GSK's “graduated approach” to Intellectual Property and Patents. She also discusses the overall impact of the approach on the pharmaceutical industry.
Continue reading
Tara Prasad Interviewed On The Zika Virus

Tara Prasad interviewed on the Zika virus

Talking to World Business Report on the BBC World Service, Research Programme Manager Tara Prasad discusses the Zika virus, the situation surrounding the development of a vaccine for it, its potential impact and affordability.
Continue reading
Wim Leereveld Interviewed In The Book Titled – 2025: Hoe Ziet De Economie Van Nederland Er In 2025 Uit

Wim Leereveld interviewed in the book titled – 2025: Hoe ziet de economie van Nederland er in 2025 uit

In attempting to foresee what the future holds for the Dutch economy, Achmea interviewed 29 thought leaders in the Netherlands. Wim Leereveld was one of these 29 thought leaders. In his interview, Wim speaks about the measurable impact that companies have on society.
Continue reading
Suzanne Wolf Interviewed On Access To Vaccines For Children

Suzanne Wolf interviewed on access to vaccines for children

Suzanne Wolf, Director of Communications at the Access to Medicine Foundation, talks with Dutch TV presenter Pernille La Lau on Koffietijd (Coffeetime), about how vaccines save lives and protect children from the threat of disease. The newly launched Access to Vaccines Index is a new tool for spurring industry change and for improving access to vaccines for everyone. (Vaccins voor iedereen). This Index is sponsored by the Dutch National Postcode Lottery.
Continue reading
Jayasree K. Iyer Discusses The Access To Medicine Index And Trends

Jayasree K. Iyer discusses the Access to Medicine Index and trends

Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation discusses the Access to Medicine Index, the role of shared value champions, how the Index is changing the pharmaceutical landscape, and what trends she’s most excited about around access to medicine.
Continue reading
Access To Medicine Foundation Consulted For List: 50 Companies Changing The World

Access to Medicine Foundation consulted for list: 50 Companies Changing the World

Fortune reached out the Access to Medicine Foundation for its first '50 Companies that are Changing the World' list. The Foundation was interviewed about the healthcare companies nominated as companies that "achieve a positive social impact as part of their business models". GSK, Novartis and Novo Nordisk are all in the top 20.
Continue reading
Tara Prasad Talks About GSK/PATH Malaria Vaccine

Tara Prasad talks about GSK/PATH malaria vaccine

Talking to World Business Report on the BBC World Service, Lead Researcher Tara Prasad discusses the GSK/PATH malaria vaccine, its potential impact and affordability.
Continue reading
Findings From The 2014 Access To Medicine Index Used In Article Analysing Pharmaceutical Companies

Findings from the 2014 Access to Medicine Index used in article analysing Pharmaceutical Companies

The Guardian looks at whether pharmaceutical companies are changing their business approach in low and middle income countries, drawing on findings on pricing practices from the 2014 Access to Medicine Index.
Continue reading
Japanese Companies Benchmarked Using Access To Medicine Index

Japanese companies benchmarked using Access to Medicine Index

Donald McNeil of the New York Times references Japanese companies' rankings in successive versions of the Access to Medicine Index, to provide a baseline for how this group of companies generally performs regarding access issues.
Continue reading
Danny Edwards On 2014 Access To Medicine Index For The UN’s In-house Magazine

Danny Edwards on 2014 Access to Medicine Index for the UN’s in-house magazine

How are pharmaceutical companies increasing access to medicine? Danny Edwards sets out the main findings of the 2014 Access to Medicine Index in the UN's in-house magazine.
Continue reading
Access To Medicine Index Referred To In ESG Matters From Allianz Global Investors

Access to Medicine Index referred to in ESG Matters from Allianz Global Investors

In an article about Access to Medicine Strategies, the Access to Medicine Index is cited as a source of insight into pharmaceutical company performances on access to medicine.
Continue reading
Tara Prasad Comments On Vaccine Pricing

Tara Prasad comments on vaccine pricing

Writing in Dutch national newspaper De Volkskrant, Lisa Koetsenruijter covers the rises in vaccine prices over recent years. Index researcher Tara Prasad explains some of the complexities of pharmaceutical pricing practices, emphasising the importance of aiming for affordability, especially in lower income market segments.
Continue reading
Wim Leereveld Talks About How The Access To Medicine Index Has Evolved Over The Years

Wim Leereveld talks about how the Access to Medicine Index has evolved over the years

In a detailed 30-minute interview, Wim Leereveld talks to Paul van Liempt about how the Access to Medicine Index has evolved since its beginnings in 2003, and about the role it now plays in stimulating global pharmaceutical companies to help change the world.
Continue reading
2014 Index Findings In The Pharmaceutical Journal

2014 Index findings in the Pharmaceutical Journal

The Pharmaceutical Journal in London creates an infographic of a range of findings from the 2014 Access to Medicine Index, including insights into the development of innovative and adapted products, equitable pricing strategies and local capacity building initiatives.
Continue reading
Leaders, Risers And Fallers In The 2014 Index Covered By The NYT

Leaders, risers and fallers in the 2014 Index covered by the NYT

Donald McNeil reports GSK's No.1 position, also noting that more than half of the companies in the 2014 Index are developing paediatric formulations of important drugs.
Continue reading
BMJ Reports That Progress Is Being Made, But Struggles Remain – 2014 Index

BMJ reports that progress is being made, but struggles remain – 2014 Index

The British Medical Journal reports that the finding that top drug companies are making drugs more accessible but are also struggling to perform in the area of corruption.
Continue reading
NOS Reports That Pharma Companies Are Active On Behalf Of 3rd World – 2014 Index

NOS reports that pharma companies are active on behalf of 3rd world – 2014 Index

Dutch public broadcaster, the NOS, publishes the 2014 ranking while reporting on the positive efforts being made by pharmaceutical companies to increase access to medicine in the 3rd world, in its coverage of the 2014 Index.
Continue reading
Economic Times Of India Covers The 2014 Index

Economic Times of India covers the 2014 Index

The Economic Times of India reports on how the efforts pharmaceutical companies are making to improve access, are undermined by corruption incidences.
Continue reading
PharmaTimes Reports On Pharma Industry Progress And Struggles As Revealed By 2014 Index

PharmaTimes reports on pharma industry progress and struggles as revealed by 2014 Index

Kevin Grogran writes about where pharmaceutical companies are doing well, and where progress remains static, as revealed by the 2014 Access to Medicine Index, also covering what the leaders are doing well and the companies that have risen or fallen the furthest.
Continue reading
De Volkskrant Covers 2014 Index, Noting Shift From Philanthropy To Business

De Volkskrant covers 2014 Index, noting shift from philanthropy to business

In his coverage of the 204 Index, Sander Heijne notes the observation that pharmaceutical companies are doing more to make medicine accessible in developing countries while also maximising growth opportunities.
Continue reading
Die Welt Covers 2014 Index In Series Of Online And Print Articles

Die Welt covers 2014 Index in series of online and print articles

Anja Ettel discusses progress made by the pharmaceutical industry while also highlighting the question of corruption, in a series of four online and print articles, including an interview with Wim Leereveld.
Continue reading
Reuters Balances Industry Progress With Policy Finding In 2014 Index Coverage

Reuters balances industry progress with Policy finding in 2014 Index coverage

Ben Hirschler from Reuters covered the 2014 Index in depth, concluding that the world's top drugmakers have improved access to medicines in developing countries, but their good work is undermined by their unethical behavior.
Continue reading
The Guardian Reports On Drivers Behind The 2014 Index

The Guardian reports on drivers behind the 2014 Index

Julia Kollewe covers the leaders, risers and fallers in the 2014 Index, setting out the drivers behind the changes and contextualising the efforts of the industry as a whole.
Continue reading
Prashant Yadav Looks Toward The Publication Of The 2014 Access To Medicine Index

Prashant Yadav looks toward the publication of the 2014 Access to Medicine Index

Writing for NextBillion.net, Prashant Yadav and Andrea Bare look toward the publication of the next Access to Medicine Index on Monday, 17 November, and discuss the Index as a tool for analysing pharmaceutical company behaviour. Prashant Yadav is a Senior Research Fellow at the William Davidson Institute (WDI) and Director of the Health Care Research Initiative at WDI. He is also a Technical sub-Committee member for the Access to Medicines Index. Andrea Bare is Senior Advisor in Market Dynamics at the William Davidson Institute.
Continue reading
FT Focuses On GSK’s Leadership In Coverage Of 2014 Index

FT focuses on GSK’s leadership in coverage of 2014 Index

Andrew Ward reports on the drivers behind changes in the Access to Medicine Index, quoting Wim Leereveld and focusing on the reasons behind GSK's No.1 position.
Continue reading
Wim Leereveld Talks To The Medicine Maker

Wim Leereveld talks to the Medicine Maker

In the launch issue of The Medicine Maker, Index CEO and Founder Wim Leereveld tells the story of how the Index came into being, and gives his view on how the industry is progressing. "I am convinced that companies are making positive long-term decisions. Companies have evolved, and so has the Index. As time goes on we have a more concrete, detailed picture of companies. With every Index we raise the bar.
Continue reading
Dr. Paul Newton Refers To Access To Medicine Index In Lancet Global Health

Dr. Paul Newton refers to Access to Medicine Index in Lancet Global Health

Writing in the September 2014 issue of The Lancet Global Health, Dr. Paul Newton et al discuss possible actions for addressing the dangers posed by falsified medicines. This includes calling for pharmaceutical companies to report all discoveries of suspect medicines to the WHO, and a possible role for independent organisations such as the Access to Medicine Index in reporting compliance. Dr. Newton leads the Wellcome Trust-Mahosot Hospital-Oxford Tropical Medicine Research Collaboration, based at Mahosot Hospital, Vientiane, in Laos. "I am convinced that companies are making positive long-term decisions. Companies have evolved, and so has the Index. As time goes on we have a more concrete, detailed picture of companies. With every Index we raise the bar.
Continue reading
IP Watch Talks To Hans Hogerzeil About How The Index Works

IP Watch talks to Hans Hogerzeil about how the Index works

IP Watch interviews Hans Hogerzeil about how the Access to Medicine Index recognises good pharma practice, and about the importance of measuring companies' efforts to increase access to medicine. Hans Hogerzeil is a Professor of Global Health at the University of Groningen, the Netherlands. He is currently interim chair of the Supervisory Board of the Access to Medicine Foundation and chairs the Expert Review Committee for the 2014 Access to Medicine Index.
Continue reading
De Volkskrant Outlines Progress Towards Global Disease Elimination

De Volkskrant outlines progress towards global disease elimination

Carlijne Vos writes about MSD (Merck & Co.'s) work in eliminating river blindness in the context of global efforts to eradicate Neglected Tropical Diseases. The Foundation's Head of Research, Jayasree Iyer, comments with regard to big pharma's role in these initiatives.
Continue reading
The Economist References The Access To Medicine Index

The Economist references the Access to Medicine Index

The Economist profiles the Global Health Innovative Technology Fund (GHIT), a Japanese research partnership focused on developing treatments for malaria, tuberculosis and Chagas disease. Several of its members are included in the Access to Medicine Index, and their rankings were referenced in the article to illustrate how the Japanese pharmaceutical companies is performing on the issue of access to medicine.
Continue reading
Bloomberg Quotes Wim Leerveld In Article On Indian IP Landscape

Bloomberg quotes Wim Leerveld in article on Indian IP landscape

Eva von Schaper writes about recent developments in the Indian IP landscape, including the role of India’s generics market. CEO and founder of the Access to Medicine Foundation, Wim Leereveld, comments on the factors that may have contributed to some of these decisions.
Continue reading
Bill Gates-What I’m Thinking

Bill Gates-What I’m Thinking

For people suffering from serious but treatable diseases like pneumonia and tuberculosis, access to drugs can mean the difference between life and death. A new report and two recent announcements are signs of progress in efforts to expand access.
Continue reading

Sign up to receive updates about our work.